AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes
Journal of Clinical Investigation · 15.05.2025 · 135 (10)
DOI: 10.1172/jci189842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.05.2025. Verfasst von Yang Gou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington Medicine Diabetes Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hyperglycemia, Diabetes Mellitus, Type 2, Neurons, Arcuate Nucleus of Hypothalamus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Growing evidence suggests that the pathogenesis of type 2 diabetes (T2D) involves dysfunctional central mechanisms, and, hence, the brain can be targeted to treat this disease. As an example, a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) can normalize hyperglycemia for weeks or months in rodent models of T2D. Convergent evidence implicates inhibition of a particular subset of neurons as a mediator of this FGF1 effect. Specifically, AgRP neurons, which are located in the hypothalamic arcuate nucleus (ARC) and are hyperactive in Lep ob/ob mice and other rodent models of T2D. To investigate whether chronic AgRP neuron inactivation mimics the antidiabetic action of FGF1, we directed an adeno-associated virus (AAV) containing a cre-inducible tetanus toxin–GFP (TeTx-GFP) cassette (or cre-inducible AAV GFP control) to the ARC of obese, diabetic male Lep ob/ob mice in which cre recombinase is expressed solely by AgRP neurons (Lep ob/ob AgRP-Cre mice). We report that over a 10-wk period of observation, hyperglycemia was fully normalized by AgRP neuron inactivation. In contrast, changes in energy homeostasis parameters (food intake, energy expenditure, body weight, and fat mass) were not observed. We conclude that in diabetic male Lep ob/ob mice, AgRP neuron hyperactivity is required for hyperglycemia but is dispensable for obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Washington Medicine Diabetes Institute, Seattle, Washington, USA.
- Ivy Brain Tumor Center, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA.
- Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, Washington, USA.
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
- NIH-NIDDK
- Department of Defense
- Novo Nordisk
- Cystic Fibrosis Foundation
Zitieren
APA
Gou, Y., Glat, M., Damian, V., Bryan, C. L., Phan, B. A., Faber, C. L., Trivedi, A., Hwang, M. K., Scarlett, J. M., Morton, G. J., & Schwartz, M. W. (2025). AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes. Journal of Clinical Investigation, 135(10). https://doi.org/10.1172/jci189842
Vancouver
Gou Y, Glat M, Damian V, Bryan CL, Phan BA, Faber CL, et al. AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes. Journal of Clinical Investigation. 2025;135(10). doi:10.1172/jci189842
BibTeX
@article{Gou2025,
author = {Gou, Yang and Glat, Micaela and Damian, Vincent and Bryan, Caeley L and Phan, Bao Anh and Faber, Chelsea L and Trivedi, Arikta and Hwang, Matthew K and Scarlett, Jarrad M and Morton, Gregory J and Schwartz, Michael W},
title = {AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {10},
doi = {10.1172/jci189842}
}
EUVIMED